Abstract
Chimeric antigen receptor (CAR) T-cell therapies have brought paradigm shift in treatment of lymphoma. Following the pivotal studies in CD19-targeted CAR T-cell therapies, three products, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) were approved by FDA for third-line treatment of large B-cell lymphoma (LBCL). The indication for axi-cel was recently expanded to follicular lymphoma (FL) after two or more lines of systemic therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
